MRNA Mar 2023 125.000 call
| Previous close | 50.66 |
| Open | 51.22 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 125.00 |
| Expiry date | 2023-03-17 |
| Day's range | 50.66 - 51.22 |
| Contract range | N/A |
| Volume | |
| Open interest | 373 |
- Yahoo Finance
COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst
Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.
- Yahoo Finance Video
Pharma earnings: COVID ‘is highly uncertain for this year,’ analyst says
Wells Fargo Managing Director Mohit Bansal joins Yahoo Finance Live to discuss pharmaceutical earnings amid COVID uncertainty, the impact of diabetic weight loss drugs on the market, and the outlook for drugmakers.
- Business Wire
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
FREMONT, Calif., February 03, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, kn
